Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Leukemia, Myeloid, Acute 7Recurrence 5Colonic Neoplasms 5Thyroid Neoplasms 4Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neuroblastoma 4Neoplasms by Site 4Lung Neoplasms 4Lung Diseases 4Head and Neck Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Breast Neoplasms 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Advanced Non-small Cell Lung Cancer × Clear all
NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡